Cover Image
市場調查報告書

卵巢癌:開發中產品分析

Ovarian Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229719
出版日期 內容資訊 英文 1780 Pages
訂單完成後即時交付
價格
Back to Top
卵巢癌:開發中產品分析 Ovarian Cancer - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 1780 Pages
簡介

卵巢癌的大多數發生在卵巢的表皮(外薄膜)。卵巢癌的徵兆和症狀,有骨盆的不舒服和疼痛,消化不良,噁心,便秘和排便週期變化,食慾不振,腰痛等。該疾病的原因,與老齡化和血統有很大的關係。

本報告提供卵巢癌治療藥的開發中產品的概要和臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

卵巢癌概要

治療藥的開發

卵巢癌:企業正在開發的治療藥

卵巢癌:大學/機關研究中的治療藥

卵巢癌:開發中產品概況

卵巢癌:企業開發中的產品

卵巢癌:大學/機關研究中的產品

卵巢癌的治療藥的開發企業

卵巢癌:治療藥的評估

藥物簡介

卵巢癌:暫停中的計劃

卵巢癌:開發中止的產品

卵巢癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7956IDB

Summary

Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H1 2016', provides an overview of the Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
  • The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Ovarian Cancer Overview
  • Therapeutics Development
  • Ovarian Cancer - Therapeutics under Development by Companies
  • Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Ovarian Cancer - Pipeline Products Glance
  • Ovarian Cancer - Products under Development by Companies
  • Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Ovarian Cancer - Companies Involved in Therapeutics Development
  • Ovarian Cancer - Therapeutics Assessment
  • Drug Profiles
  • Ovarian Cancer - Dormant Projects
  • Ovarian Cancer - Discontinued Products
  • Ovarian Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ovarian Cancer, H1 2016
  • Number of Products under Development for Ovarian Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Development by Companies, H1 2016 (Contd..19)
  • Number of Products under Development by Companies, H1 2016 (Contd..20)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Development by Companies, H1 2016 (Contd..28)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016
  • Ovarian Cancer - Pipeline by 4SC AG, H1 2016
  • Ovarian Cancer - Pipeline by AB Science SA, H1 2016
  • Ovarian Cancer - Pipeline by AbbVie Inc., H1 2016
  • Ovarian Cancer - Pipeline by AbGenomics International, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Ovarian Cancer - Pipeline by Advantagene, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016
  • Ovarian Cancer - Pipeline by Alchemia Limited, H1 2016
  • Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Ovarian Cancer - Pipeline by Almac Discovery Limited, H1 2016
  • Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc., H1 2016
  • Ovarian Cancer - Pipeline by Alteogen Inc., H1 2016
  • Ovarian Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Amgen Inc., H1 2016
  • Ovarian Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Ovarian Cancer - Pipeline by ANP Technologies, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Antoxis Limited, H1 2016
  • Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016
  • Ovarian Cancer - Pipeline by Aphios Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Aposense Ltd., H1 2016
  • Ovarian Cancer - Pipeline by Aprea AB, H1 2016
  • Ovarian Cancer - Pipeline by arGEN-X BV, H1 2016
  • Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H1 2016
  • Ovarian Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Arog Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by ArQule, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Ovarian Cancer - Pipeline by Arvinas, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H1 2016
  • Ovarian Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
  • Ovarian Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2016
  • Ovarian Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Ovarian Cancer - Pipeline by Bayer AG, H1 2016
  • Ovarian Cancer - Pipeline by BeiGene, Ltd., H1 2016
  • Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2016
  • Ovarian Cancer - Pipeline by BioMoti Limited, H1 2016
  • Ovarian Cancer - Pipeline by BioNTech AG, H1 2016
  • Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Bioo Therapeutics, H1 2016
  • Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Ovarian Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Ovarian Cancer - Pipeline by Cavion LLC, H1 2016
  • Ovarian Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Ovarian Cancer - Pipeline by Celprogen, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Celsion Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Celyad SA, H1 2016
  • Ovarian Cancer - Pipeline by Ceronco Biosciences, H1 2016
  • Ovarian Cancer - Pipeline by CerRx, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Chikujee Therapeutics, H1 2016
  • Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2016
  • Ovarian Cancer - Pipeline by CohBar, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Commence Bio, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Compliment Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016
  • Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Ovarian Cancer - Pipeline by CritiTech, Inc., H1 2016
  • Ovarian Cancer - Pipeline by CTI BioPharma Corp., H1 2016
  • Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by CytRx Corporation, H1 2016
  • Ovarian Cancer - Pipeline by CZ BioMed Corp, H1 2016
  • Ovarian Cancer - Pipeline by Debiopharm International SA , H1 2016
  • Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H1 2016
  • Ovarian Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Ovarian Cancer - Pipeline by EirGenix Inc., H1 2016
  • Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Ovarian Cancer - Pipeline by Endocyte, Inc., H1 2016
  • Ovarian Cancer - Pipeline by EntreChem, S.L., H1 2016
  • Ovarian Cancer - Pipeline by Epigen Biosciences, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Ovarian Cancer - Pipeline by Fate Therapeutics, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Forty Seven Inc., H1 2016
  • Ovarian Cancer - Pipeline by Fujifilm Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H1 2016
  • Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H1 2016
  • Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2016
  • Ovarian Cancer - Pipeline by Gene Techno Science Co., Ltd., H1 2016
  • Ovarian Cancer - Pipeline by Genelux Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Genentech, Inc., H1 2016
  • Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H1 2016
  • Ovarian Cancer - Pipeline by Genisphere Inc., H1 2016

List of Figures

  • Number of Products under Development for Ovarian Cancer, H1 2016
  • Number of Products under Development for Ovarian Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top